Sisomicin

Summary

Sisomicin (CHEMBL221886) is a phase-3 clinical-stage small molecule (ATC J01GB08); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01GB08
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 447.5 Da · C19H37N5O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL221886
Name	Sisomicin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	36119
ChEBI	CHEBI:9169
ATC	J01GB08
Molecular formula	C19H37N5O7
Molecular weight	447.5
InChIKey	URWAJWIAIPFPJE-YFMIWBNJSA-N

SMILES: C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O

IUPAC name: (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

Also known as: Rickamicin, SCH 13475, Sisomicin, Sisomicina, Sisomicine, Sissomicin, sisomicin, SISOMICIN, SISOMICINE

Parent form; salt/anhydrous children: CHEMBL3989471

Patent coverage: 3,762 distinct patent families (13,520 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
bacterial infectious disease	3	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00202891	PHASE4	WITHDRAWN	Sisomicin Cream Vs Nadifloxacin Cream in Primary Pyodermas (Study P04460)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).